First look: how kidneys handle new Weight-Loss drug
NCT ID NCT07429045
Summary
This early-stage study tested how a single dose of an experimental weight-loss drug, AMG 133, is processed by the body in people with normal kidney function and in people with various levels of kidney impairment. The main goal was to see if the drug behaves differently in people with kidney problems and to check for safety. It involved 44 adults who were overweight or had obesity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdvancedPharma CR LLC
Miami, Florida, 33147-4040, United States
-
Floridian Clinical Research, LLC
Miami Lakes, Florida, 33016, United States
-
Omega Research Group, LLC - Orlando
Orlando, Florida, 32806-1133, United States
-
Orange County Research Center
Lake Forest, California, 92630, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809-3017, United States
Conditions
Explore the condition pages connected to this study.